An immnosuppressive drug, cyclosporine-A acts like anti-depressant for rats under unpredictable chronic stress

Journal of Medical and Dental Sciences

Volumn 50, Issue 1, 2003, Pages 93-100

  Fujisaki, Chieko ^a   Utsuyama, Masanori ^a   Kuroda, Yasukazu ^a   Watanabe, Akiko ^a   Seidler, Heinrich ^a   Watanabe, Shigeru ^b   Kitagawa, Masanobu ^a   Hirokawa, Katsuiku ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Behavior; Cyclosporine; Depressive; Imipramine; Neurotransmitter

Indexed keywords

ANTIDEPRESSANT AGENT; BIOGENIC AMINE; CYCLOSPORIN; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT;

ADRENAL GLAND; ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; BEHAVIOR; BIOSYNTHESIS; CHRONIC DISEASE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; FISCHER 344 RAT; FRONTAL LOBE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METABOLISM; MOTOR ACTIVITY; ORGAN SIZE; RAT; REACTION TIME; STRESS;

ADRENAL GLANDS; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR; BIOGENIC MONOAMINES; CHRONIC DISEASE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FRONTAL LOBE; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; MALE; MOTOR ACTIVITY; ORGAN SIZE; RATS; RATS, INBRED F344; REACTION TIME; STRESS;

EID: 0038548556     PISSN: 13428810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Caccavo D, Lagana B, Mitterhofer AP, et al. Long term treatment of systemic lupus erythematosus with cyclosporine A. Arth Rheum 1997;40:27-35.
2. Borlongan CV, Stahl CE, Fujisaki T, et al. Cyclosporine-A induced hyperactivity in rats: is it mediated by immunosuppression, neurotrophism, or both? Cell Transplant 1999;8:153-9.
3. Durrant S, Chipping PM, Palmer S, et al. Cyclosporine A methylpredonisolone, and convultions. Lancet 1982;2:829-30.
4. Fazakerley JK, Webb HE. Cyclosporine, blood-brain barrier, and multiple sclerosis. Lancet 1985;2:889-90.
5. Teshima T, Miyoshi T, Ono M. Cyclosporine- related encephalopathy following allogenic bone marrow transplantation. Int J Hematol 1996;63:161-4.
6. Famiglio L, Racusen L, Barbara F, et al. Central nervous system toxicity of cyclosporine in a rat model. Transplant 1989;48:316-21.
7. Borlongan CV, Freeman TB, Scorcia TA, et al. Cyclosporine-A increases spontaneous and dopamine agonist-induced locomotor behavior in normal rats. Cell Transplant 1995;4:65-73.
8. Von Horsten S, Exton MS, Voge J, et al. Cyclosporine A affects open field behavior in DA rats. Pharmacol Biochem Behav 1998;60:71-6.
9. Esquifino AL, Moreno ML, Arce A, et al. Effects of cyclosporine at the hypothalamic-pituitary axis in pituitary-grafted young female rats. J Endocrinol 1995;144:159-64.
10. Shuto H, Kataoka Y, Kanaya A, et al. Enhancement of serotonergic neural activity contributes to cyclosporine-induced tremors in mice. Eur J Pharmacol 1998;341:33-7.
11. Begley DJ, Squires LK, Zlokovic BV, et al. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporine A. J Neurochem 1990;55:1222-30.
12. Pelestine AG, Nussenblatt RB, Chan C. Cyclosporine penetration into the anterior chamber and cerebrospinal fluid. Am J Ophthalmol 1985;99:210-1.
13. Chopin P, Briley N. Animal model of anxiety: The effect of compounds that modify 5-HT neurotransmission. Trends Pharmacol Sci 1987;8:383-8.
14. Rodrigez EEL, Gonzalez AS, Cabrera R. A further analysis of behavioral and endocrine effects of undepredictable chronic stress. Physiol Behav 1988;43:789-95.
15. Hedou G, Pryce C, Di Ioril L, et al. An automated analysis of rat behavior in the forced swim test. Pharmacol Biochem Behav 2001;70:65-76.
16. Schechter MD, Chance WT. Non-specificity of "behavioral despair" as an animal model of depression. Eur J Pharmacol 1979;60:139-42.
17. Katz RJ, Baldrighi G. Animal model of depression: Test of three structurally and pharmacologically novel antidepressant compounds. Pharmacol Biochem Behav 1981;16:969-72.
18. Rosecrans JA, Robinson SE, Johnson JH, et al. Neuroendcrine, biogenic amine and behavioral responsiveness to a repeated foot-shock-induced analgesia (FSIA) stressor in Sprague-Dawley (CD) and Fischer-344 (SDF) rats. Brain Res 1986;382:71-80.
19. Holland HC, Weldon E. A note on a new technique of recording ambulation in the open field test and its validation. Acta Psychol (Amst) 1968;28:293-300.
20. Ryozhova LI, Kulagin DA, Lopatina NG. Correlate variability in motor activity and emotionality in selecting rats for high and low values of active avoidance conditioned reflexes. Genetika 1983;19:121-5.
21. Bullush LJ, Reid SG, North D. The functional significance of biochemical alterations in streptozocin-induced diabetes. Physiol Behav 1991;50:973-81.
22. Hennesy MB, O'Neil DR, Becker LA, et al. Effects of centrally administered corticotrophin-releasing factor (CRF) and a-helical CRF on the vocalizations of isolations of isolated guinea pig pups. Pharmacol Biochem Behav 1992;43:35-43.
23. Van Dijken HH, Van der Heyden JA, Mos J, et al. Inescapable footshocks induce progressive and long-lasting behavioral changes in male rats. Physiol Behav 1992;51:787-94.
24. Bandini A, Cabib S, Puglisi AS. Chronic stress induces strain-dependent sensitization to the behavioral effects of amphetamine in the mouse. Pharmacol Biochem Behav 1992;43:53-60.
25. Lee EHY, Tang YP, Chai CY. Stress and corticotrophin-releasing factor potentiate center region activity of mice in an open field. Psychopharmacology 1987;93:320-3.
26. Gelal A, Gumustekin M, Kalkan S, et al. Effects of subchronic parathion exposure on cyclosporine pharmacokinetics in rats. J Toxicol Environ Health A 2001;62:289-94.
27. Crawley J, Goodwin FK. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980;13:167-70.
28. Goldstein LE, Rasmusson AM, Bunney BS, et al. Role of the amygdala in the coordination of behavioral, neuroendocrine, and prefrontal cortical monoamine responses to psychological stress in the rats. J Nuerosci 1996;16:4787-98.
29. Shanks N, Griffiths J, Anisman H. Norepinephrine and serotonin alterations following chronic stressor exposure: mouse strain differences. Pharmacol Biochem Behav 1994;49:57-65.
30. Oades RD, Taghzouti K, Rivwet JM, et al. Locomotor activity in relation to dopamine and noradrenaline in the nucleus accumbens, septal and frontal areas: a 6-hydroxydopamine study. Neuropsychobiology 1986;16:37-42.
31. Linner L, Arborelius L, Nomikos C, et al. Locus coerelues activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of alpha 2-adrenoceptor blockade. Biol Psychiatry 1999;46:766-74.
32. Hellhammar DH, Rea MA, Bell M, et al. Learned helplessness: Effects on brain monoamines and the pituitary-gonadal axis. Pharmacol Biochem Behav 1984;21:481-5.
33. Stanford JA, Muscat R, O' Connor JJ, et al. Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamin. Psychopharmacology Berl 1991;105:275-82.
34. Kitamura Y, Itano Y, Kubo T et al. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J Neuroimmunol 1994;50:221-4.
35. Esposito P, Gheorghe D, Kandere K, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001;888:117-27.
36. Wijisman JA, Shivers RR. Heat stress affects blood-brain barrier permeability to horseradish peroxidase in mice. Acta Neuropathol 1993;86:49-54.
37. Tollermar J, Ringden O, Ericzon BG, et al. Cyclosporine-associated central nervous system toxicity. N Engl J Med 1988;24:788-9.
38. Leonardi A, DeFranchis G, Fregona IA, et al. Effects of cyclosporine A on human conjunctival fibroblasts. Arch Ophthalmol 2001;119:1512-7.
39. Di Padova FE. Pharmacology of cyclosporine V. Pharmacological effects on immune function: in vitro studies. Pharmacol Reviews. 1989;41:382-92.
40. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002;5:375-88.